New Analyses on Terbinafine Susceptibility and Mycological Cure Outcomes with MOB-015 Published in Journal of Fungi – Moberg Pharma

Moberg Pharma AB announced the publication of new analyses demonstrating potent antifungal activity of terbinafine against dermatophytes causing onychomycosis. Importantly, mycological cure with Mob-015 was achieved across the full range of baseline terbinafine susceptibility, including in patients with reduced in vitro susceptibility.

The analyses are based on data from the previously completed North American Phase 3 study evaluating daily treatment with Mob-015 for 48 weeks. The analyses included 506 dermatophyte isolates from onychomycosis patients. Only 3.2% baseline isolates showed elevated MIC values (≥0.5 µg/ml). Among Mob-015-treated patients with evaluable end-of-study results, 74.3% achieved mycological cure, including two of three patients with elevated baseline MIC values.

The work was conducted in collaboration with Professor Mahmoud Ghannoum at Case Western Reserve University in Cleveland, Ohio.

“These results are encouraging, particularly given the increasing attention to antifungal resistance. Terbinafine showed potent activity against the vast majority of isolates, and Mob-015 achieved mycological cure across the full range of baseline susceptibility. The findings further strengthen the scientific foundation for Mob-015.” – Amir Tavakkol, CSO of Moberg Pharma.

The article, “In Vitro Terbinafine Susceptibility of Dermatophytes and Mycological Cure Outcomes from a Multicenter Phase III Onychomycosis Trial,” is published in Journal of Fungi, 2026, 12(10), 739 and is available here.